Philip Toleikis, PHD, MSC

Since joining Sernova, Dr. Philip Toleikis has been instrumental in securing multiple non-dilutive and equity financings, in developing Sernova’s regenerative medicine therapeutics technology strategic approach, overseeing its worldwide Cell Pouch System patent portfolio, and key licensing, acquisitions and collaborative partnerships. He has led his team through successful product manufacturing, preclinical and clinical development in North America. Under his management, Sernova has demonstrated first-in-world results including enduring blood levels of C-peptide and key initial efficacy indicators in its ongoing Phase I/II type 1 diabetes clinical trial. Previously, he was VP R&D at Angiotech Pharmaceuticals and has also provided consulting for medical device, combination product and pharmaceutical companies. Dr. Toleikis authored over 100 patents and scientific publications. He earned his Ph.D. in Medicine, Pharmacology and Therapeutics from the University of British Columbia.